Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions

Qiuying Li1 Department of Drug Clinical Trial Management Agency, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of China

Hua Huo1 Department of Drug Clinical Trial Management Agency, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of China

Wenli Hu1 Department of Drug Clinical Trial Management Agency, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of China

Yin Sui1 Department of Drug Clinical Trial Management Agency, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of China

Yunbiao Tang1 Department of Drug Clinical Trial Management Agency, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of ChinaCorrespondence[email protected] [email protected]

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date